Compare TG Therapeutics Inc (TGTX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Block Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Block Inc trades at $79.83 (market cap $47.19B). The key difference: Block Inc is far larger — about 5.7× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| TGTX | XYZ | |
|---|---|---|
Market Cap | $8.26B | $47.19B |
Sector | Health | Technology |
52-Week High | $59.06 | $81.81 |
52-Week Low | $26.39 | $49.04 |
Enterprise Value | $8.50B | $42.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
XYZ trades at $80.38, up 0.55% today, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, but net income margin fell to 3.3% in 2025. The stock is supported by positive sentiment from Zacks upgrades and momentum coverage, though it faces risks from a recent $45 million settlement and mixed cash flow trends.
The outlook is cautiously optimistic, with a consensus price target of $89.64 offering ~12% upside. Key opportunities include earnings growth and Cash App strength, but risks involve credit losses, regulatory scrutiny, and a high P/E ratio of 61.95. Institutional selling and insider sales add near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
